Treatment of pediatric multiple sclerosis

Area of Science:

• Neurology
• Pediatrics
• Immunology

Background:

• Pediatric multiple sclerosis (MS) recognition and diagnosis have risen in the last decade.
• The availability of MS treatments and research into pediatric use has also grown significantly.

Purpose of the Study:

• To review current treatment strategies for pediatric multiple sclerosis (MS).
• To discuss the use of off-label therapies and emerging treatment options for children with MS.

Main Methods:

• Review of current literature on pediatric multiple sclerosis (MS) treatment.
• Discussion of first-line and second-line therapies, including injectables and orals.
• Consideration of acute exacerbation management and symptomatic treatment.

Main Results:

• Injectable therapies (glatiramer acetate, interferon beta) offer about a 30% reduction in relapses as first-line options.
• Second-line therapies like natalizumab may offer higher efficacy but carry increased risks.
• Corticosteroids are recommended for severe attacks; IV immunoglobulin or plasma exchange may be needed if unresponsive.

Conclusions:

• Prompt initiation of disease-modifying therapy is essential for pediatric MS.
• Patient and family involvement in treatment decisions promotes adherence.
• Ongoing research into new therapies, including oral agents, holds promise for pediatric MS patients.